934736-50-2

Basic information

• Product Name: N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine
• Synonyms: N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine
• CAS NO: 934736-50-2
• Molecular Weight: 451.522
• Mol File: 934736-50-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine(CAS DataBase Reference)
• NIST Chemistry Reference: N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine(934736-50-2)
• EPA Substance Registry System: N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine(934736-50-2)

Safety Data

• Hazardous Substances Data: 934736-50-2(Hazardous Substances Data)

Upstream product

• 6306-52-1 L-valine methylester hydrochloride 
• 72-18-4 L-valine 
• 944467-25-8 N-valeryl-N-[(2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl]-L-valine methyl ester 
• 944467-24-7 N-valeryl-N-[(2'-(N'-(isobutoxycarbonyloxy)carbamimidoyl)biphenyl-4-yl)methyl]-L-valine methyl ester 
• 944467-23-6 N-valeryl-N-[(2'-(N'-hydroxycarbamimidoyl)biphenyl-4-yl)methyl]-L-valine methyl ester 
• 137863-90-2 methyl 2-(N-((2'-cyanobiphenyl-4-yl)methyl)pentanamido)-3-methylbutanoate 
• 137863-89-9 N-[(2'-cyanobiphenyl-4-yl)-methyl]-(L)-valine methyl ester 

Relevant articles and documents

Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect

A series of novel angiotensin II type 1 receptor antagonists were prepared. Radioligand binding assay suggested that compounds 1b and 1c could be recognized by the AT1 receptor with an IC50 value of 1.6 ± 0.09 nM and 2.64 ± 0.7 nM, respectively. In vivo anti-hypertension experiments showed that compounds (1a, 1b, 1c, 1e) elicited a significant decrease in SBP and DBP of spontaneous hypertensive rats (SHRs). The antihypertensive effects maintained for 10 h, which indicated that these compounds had a favorable blood pressure-lowering effect. Acute toxicity testing suggested that the LD50 value of compound 1b was 2316.8 mg/kg which was lower than valsartan (LD50 = 307.50 mg/kg) but higher than losartan (LD50 = 2248 mg/kg). So they could be considered as novel anti-hypertension candidates and deserved for further investigation.